Your browser doesn't support javascript.
Update on omicron variant: What we know so far.
Choudhary, Gajendra; Prajapat, Manisha; Kumaravel, J; Prabha, Praisy K; Sarma, Phulen; Handa, Vrishbhanu; Kaur, Harminder; Patel, Ajay Prakash; Medhi, Bikash.
  • Choudhary G; Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Prajapat M; Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Kumaravel J; Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Prabha PK; Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Sarma P; Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Handa V; Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Kaur H; Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Patel AP; Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Medhi B; Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Indian J Pharmacol ; 54(1): 41-45, 2022.
Article in English | MEDLINE | ID: covidwho-1766049
ABSTRACT
The new omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in South Africa in November 2021 has been declared as a Variant of Concern by the World Health Organization. This variant has been found to carry multifold mutations that have not been observed in any of the variants detected so far. The majority of these mutations are present in spike protein, contributing to its ability to escape the currently available neutralizing antibodies and vaccines, as well as increasing the chances of reinfection. This brief communication provides an insight into mutations detected in the omicron variant and their impact on currently available interventions against SARS-CoV-2 and the need for a booster dose. We also discuss the severity status of infection due to this variant. Additionally, we highlight the hypothesis supporting the association of high HIV prevalence and the appearance of the omicron variant of SARS-CoV-2 in immune-compromised individuals.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Envelope Proteins / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Indian J Pharmacol Year: 2022 Document Type: Article Affiliation country: Ijp.ijp_955_21

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Envelope Proteins / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Indian J Pharmacol Year: 2022 Document Type: Article Affiliation country: Ijp.ijp_955_21